Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.

Ghanima W, Lee SY, Barsam S, Miller A, Sandset PM, Bussel JB.

Br J Haematol. 2012 Sep;158(6):811-4. doi: 10.1111/j.1365-2141.2012.09227.x. Epub 2012 Jul 23. No abstract available.

PMID:
22816787
2.

Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.

Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R.

Am J Hematol. 2016 May;91(5):E293-5. doi: 10.1002/ajh.24341. Epub 2016 Apr 4.

PMID:
26910388
3.

[Development of thrombopoietin receptor agonists].

Miyakawa Y.

Rinsho Ketsueki. 2009 Oct;50(10):1434-43. Review. Japanese. No abstract available.

PMID:
19915352
4.

A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.

Khellaf M, Viallard JF, Hamidou M, Cheze S, Roudot-Thoraval F, Lefrere F, Fain O, Audia S, Abgrall JF, Michot JM, Dauriac C, Lefort S, Gyan E, Niault M, Durand JM, Languille L, Boutboul D, Bierling P, Michel M, Godeau B.

Haematologica. 2013 Jun;98(6):881-7. doi: 10.3324/haematol.2012.074633. Epub 2013 Feb 26.

5.

Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.

Magnano L, Enríquez H, Esteve J, Cervera R, Espinosa G.

J Rheumatol. 2014 Sep;41(9):1895-6. doi: 10.3899/jrheum.140080. No abstract available.

PMID:
25179983
6.

[Management of refractory ITP with thrombopoietin receptor agonists].

Tomiyama Y.

Rinsho Ketsueki. 2011 Aug;52(8):627-32. Review. Japanese. No abstract available.

PMID:
21897068
7.

Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.

Arumugaswamy A, He S, Quach H, Brotchie J, Grigg A.

Intern Med J. 2014 May;44(5):519-21. doi: 10.1111/imj.12406. No abstract available.

PMID:
24816314
8.

Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.

Tsukamoto S, Nakaseko C, Takeuchi M, Kumagai K, Komatsu T, Tanaka H, Hara S, Koizumi M, Imai H, Yokota A, Takeuchi M, Inokuchi K, Matsuura Y, Aotsuka N, Wakita H.

Br J Haematol. 2013 Oct;163(2):286-9. doi: 10.1111/bjh.12483. Epub 2013 Jul 17. No abstract available.

PMID:
23862773
9.

Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.

Gudbrandsdottir S, Frederiksen H, Hasselbalch H.

Platelets. 2012;23(6):423-9. doi: 10.3109/09537104.2011.634931. Epub 2011 Dec 20.

PMID:
22185370
10.

Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective.

Ruggeri M.

Am J Hematol. 2012 Oct;87(10):946-7. doi: 10.1002/ajh.23298. Epub 2012 Jul 27. No abstract available.

11.

Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.

Meyer O, Salama A.

Onkologie. 2011;34(1-2):10-3. doi: 10.1159/000323347. Epub 2011 Jan 17.

PMID:
21346379
12.

Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials.

Catalá-López F, Corrales I, Martín-Serrano G, Tobías A, Calvo G.

Med Clin (Barc). 2012 Oct 20;139(10):421-9. doi: 10.1016/j.medcli.2011.11.023. Epub 2012 Jan 23. Review.

PMID:
22266082
13.

Thrombopoietin-receptor agonists.

Basciano PA, Bussel JB.

Curr Opin Hematol. 2012 Sep;19(5):392-8. doi: 10.1097/MOH.0b013e328356e909. Review.

PMID:
22872157
14.

Sustaining platelet counts in chronic ITP.

Nurden AT.

Lancet. 2011 Jan 29;377(9763):358-60. doi: 10.1016/S0140-6736(10)61090-2. Epub 2010 Aug 23. No abstract available.

PMID:
20739056
15.

TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.

Zeng Y, Duan X, Xu J, Ni X.

Cochrane Database Syst Rev. 2011 Jul 6;(7):CD008235. doi: 10.1002/14651858.CD008235.pub2. Review.

PMID:
21735426
16.

Platelet response as the basis for approval in chronic immune (idiopathic) thrombocytopenic purpura (ITP): a regulatory perspective.

Pignatti F, Flores B, Jonsson B.

Am J Hematol. 2012 Oct;87(10):943-4. doi: 10.1002/ajh.23300. Epub 2012 Sep 17. No abstract available.

17.

Platelet count or bleeding as the outcome in ITP trials?

Arnold DM.

Am J Hematol. 2012 Oct;87(10):945-6. doi: 10.1002/ajh.23299. Epub 2012 Jul 27. No abstract available.

18.

Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia.

Álvarez Román MT, Fernández Bello I, Arias-Salgado EG, de Paz R, Jiménez Yuste V, Martín Salces M, Butta NV.

Br J Clin Pharmacol. 2014 Sep;78(3):674-6. doi: 10.1111/bcp.12370. No abstract available.

19.

[Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim].

Rodríguez Vargas B, Serna Pérez J, Bermejo Vicedo T.

Farm Hosp. 2013 May-Jun;37(3):265-6. doi: 10.7399/FH.2013.37.3.548. Spanish. No abstract available.

20.

TPO-receptor agonists in ITP: a clinician's navigation between Scylla and Charybdis.

Rodeghiero F.

Am J Hematol. 2012 Oct;87(10):943. doi: 10.1002/ajh.23301. Epub 2012 Jul 27. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk